Navigation Links
Vermillion Announces First Quarter 2008 Financial Results and Business Progress
Date:5/15/2008

from $5.7 million in the same period last year. The decrease was due primarily to restructuring of personnel and reduced general and administrative expenses.

The Company's net loss for the first quarter of 2008 was $4.8 million, compared to $6.0 million for the same period in 2007. Basic and diluted net loss for the first quarter of 2008 was $0.76 per share based on 6.38 million total shares outstanding, compared to a basic and diluted net loss of $1.54 per share based on 3.92 million total shares outstanding for the same period in 2007. Earnings per share calculations are on a post reverse stock split basis.

At March 31, 2008, the Company's cash, short- and long-term investments totaled $14.3 million, compared to $20.4 million at December 31, 2007. Net cash used in operating activities in the first quarter of 2008 was $5.5 million. The semi-annual payment of interest of approximately $0.6 million on the senior convertible note is due during the first and third quarters, which results in higher net cash outflows for these quarters. Vermillion continues to diligently manage expenses and cash utilization.

Recent Highlights and Accomplishments

During the first and into the second quarter of the year, Vermillion achieved numerous milestones in its three leading diagnostic programs and continued to progress in its corporate development efforts.

-- PAD Diagnostic Program

* Established a clinical steering committee to provide advice on

studies to support registration of VASCLIR with the FDA and to

further potential market adoption.

* Presented data from a study providing further confirmation that the

Company's test may aid in the diagnosis of PAD. The research, which

was presented at the American College of Cardiology 57th Annual

Scientific Session, suggests that such a test may be useful in

helping determine a patient's risk for de
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- , - Results From a ... Arthritis in Seven Major Industrialized Countries , , ... say their disease, impacts their ... living with rheumatoid arthritis find shopping for gifts, ... presents most, difficult to do, ...
(Date:12/11/2009)... (Nasdaq: DNDN ) announced today that the ... exercised in full their option to purchase an ... public offering price of $24.75 per share. ... of the offering to an aggregate of 17,250,000 ... receive net proceeds from the offering of approximately ...
(Date:12/11/2009)... a new explanation for differences in the severity of mental ... gene, the more serious the handicap. The genetic defect is ... is the amount of copies of the GDI1 gene that ... American Journal of Human Genetics , and are the result ... VIB, a life sciences research institute in Flanders, Belgium at ...
(Date:12/11/2009)... Ambit Biosciences Corporation announced today the enrollment and dosing ... Center of the first patient in the ACE ( ... fficacy) Phase 2 pivotal trial in patients with relapsed ... a novel, orally available, potent and highly selective small ... kinase-3 (FLT3) inhibitor. The ACE study is designed ...
Breaking Biology Technology:Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Amount of gene surplus determines severity of mental retardation in males 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5
... , ... • chemiluminescence , , ... enzymes exist, their activities having wide-ranging regulatory responses. Many kinases ... as inflammation and cancer, so identifying modulators of kinase and ...
... ... apoptosis • multiplexing • cell based assays ... Apoptosis represents a gene-directed, morphologically and biochemically distinct form of ... of disease states such as cancer, AIDS, neurodegenerative diseases, and ischaemic stroke. ...
... , ... receptor binding assay • LEADseeker • SPA Imaging Beads, ... Chemo-attractant cytokines (chemokines) are low molecular weight, pro-inflammatory cytokines with potent ... are classified into four families (CXC, CC, C, and CXC3) based ...
Other Biology Technology:Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 2Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 3Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 4The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 2The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 3The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 4The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 5The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 6The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 7The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 2The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 3The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 4
(Date:12/14/2009)... study to date of the proteins in a species ... clues to how similar regeneration could be induced in ... at Indiana University-Purdue University Indianapolis and colleagues investigated over ... a type of salamander that has the unique natural ... with the hope that this knowledge will contribute to ...
(Date:12/14/2009)... the United Nations Framework Convention on Climate Change ... hosted the ,Bend the Trend, event on Sunday ... and premiere the screening of the new ,Environmental ... Europe, a joint project of the European Environment ... ESA, is a series of short films showing ...
(Date:12/13/2009)... resolved a question about how a popular class ... biosensors that reveal previously hidden components of chemical ... and hallucinations characterize the illness, people with schizophrenia ... in a particular order, difficulties that interfere with ... well, said Lee Schroeder, a student in the ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2'Environmental Atlas of Europe' unveiled at COP15 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2IWillAgain com Launches Online Community for Athletes Overcoming Accident Illness or Injury 61623 1IWillAgain com Launches Online Community for Athletes Overcoming Accident Illness or Injury 61623 2Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 61619 1Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 61619 2Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 61619 3Knome Launches First Platform Agnostic Human Genome Sequencing and Analysis Service for Researchers 14898 1Knome Launches First Platform Agnostic Human Genome Sequencing and Analysis Service for Researchers 14898 2Knome Launches First Platform Agnostic Human Genome Sequencing and Analysis Service for Researchers 14898 3
... new mission for its Earth science program: to study ... rather than as individual parts. To acknowledge this milestone, ... the accomplishments of 20 years of NASA,s Earth system ... ahead. , Reporters are invited to attend "NASA ...
... cutting-edge medical research, a biomedical engineer at UC Davis ... treatment for infants born with disorders that cause the ... The new approach is based on creating a synthetic ... it could also lead to advances in treating various ...
... . , When someone,s knee hurts with every ... badly damaged that the bones rub together when walking. Medical ... so that patients with such knee problems can walk free ... and blood vessels in the laboratory. The research scientists place ...
Other Biology News:UC Davis bioengineer receives Hartwell Foundation grant to address skull fusion disorder of infants 2Non-wovens as scaffolds for artificial tissue 2
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Inquire...
1M stock solution (238mg/ml)...
...
Biology Products: